These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23587174)

  • 1. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.
    Silva Miguel L; Silva Miguel N; Inês M
    Cost Eff Resour Alloc; 2013 Apr; 11(1):8. PubMed ID: 23587174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
    Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G
    Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    Baldwin DS; Schweizer E; Xu Y; Lyndon G
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
    De Salas-Cansado M; Olivares JM; Alvarez E; Carrasco JL; Barrueta A; Rejas J
    Clinicoecon Outcomes Res; 2012; 4():157-68. PubMed ID: 22745564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
    Rickels K; Pollack MH; Sheehan DV; Haskins JT
    Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
    Meoni P; Hackett D; Lader M
    Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL; Montgomery S; Francois C
    Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
    Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
    J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
    Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
    Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M; Álvarez E; Olivares JM; Carrasco JL; Ferro MB; Rejas J
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder.
    Sobocki P; Ekman M; Ovanfors A; Khandker R; Jönsson B
    Int J Clin Pract; 2008 Apr; 62(4):623-32. PubMed ID: 18284439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
    Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
    Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.
    Sheehan DV
    J Clin Psychiatry; 1999; 60 Suppl 22():23-8. PubMed ID: 10634352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
    J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.